No black box warning on record for Caplyta

As of the latest FDA labeling reviewed, Caplyta (LUMATEPERONE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Caplyta medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis: Increased incidence of cerebrovascular adverse reactions (e.g., stroke and transient ischemic attack). ( 5.3 ) Neuroleptic Malignant Syndrome: If NMS is suspected, immediately discontinue CAPLYTA and provide intensive symptomatic treatment and monitoring. ( 5.4 ) Tardive Dyskinesia: If

No black box warning on record for Caplyta

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis: Increased incidence of cerebrovascular adverse reactions (e.g., stroke and transient ischemic attack). ( 5.3 ) Neuroleptic Malignant Syndrome: If NMS is suspected, immediately discontinue CAPLYTA and provide intensive symptomatic treatment and monitoring. ( 5.4 ) Tardive Dyskinesia: If

Caplyta Black Box Warning

No black box warning on record for Caplyta

Other warnings & precautions

Caplyta Black Box Warning

No black box warning on record for Caplyta

Other warnings & precautions